Mirum Pharmaceuticals, Inc. Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -52.67M-103.38M-84.25M-135.66M-163.41M-87.94M
Share-based Compensation 6.07M12.55M23.09M27.01M35.02M48.44M
Gains from Sales and Divestitures 0.13M0.13M0.12M
Gains from Investment Securities 3.70M5.07M6.87M3.51M1.05M9.63M
Non-cash Items 40.63M32.64M51.65M131.78M
Cash from Operations -39.36M-89.08M-132.76M-120.14M-70.94M10.32M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.33M0.32M0.14M1.70M1.73M
Amortization of Deferred Charges 0.18M0.32M1.12M1.66M
Depreciation & Amortization (CF) 0.14M0.30M0.59M3.24M10.83M23.63M
Change in Working Capital
Change in Receivables 20.73M43.97M11.43M
Change in Inventory 0.49M3.45M0.97M3.17M
Change in Accured Expenses 10.06M3.68M22.66M7.64M30.78M40.31M
Other Working Capital Changes 2.69M1.83M4.01M3.68M3.60M1.50M
Investing Activities
Capital Expenditures 0.28M0.23M0.02M0.28M0.11M0.99M
Change in Intangibles 19.00M20.00M20.00M
Acquisitions 212.76M
Change in Acquisitions & Divestments 24.50M85.90M155.60M140.30M153.00M19.89M
Cash from Investing Activities -127.78M37.87M48.55M7.70M-107.20M-90.12M
Financing Activities
Cash from Financing Activities 127.18M181.29M73.47M109.09M336.60M17.70M
Additional items
Exchange Rate Effect -0.03M0.03M-0.00M0.01M-0.13M-1.30M
Change in Cash -39.99M130.12M-10.75M-3.34M158.32M-63.40M
Free Cash Flow -39.64M-89.30M-132.78M-120.41M-71.05M9.33M
Net Cash Flow -39.97M130.09M-10.74M-3.35M158.46M-62.10M